These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

100 related articles for article (PubMed ID: 18804182)

  • 21. Ligand-based targeted therapy for cancer tissue.
    Das M; Mohanty C; Sahoo SK
    Expert Opin Drug Deliv; 2009 Mar; 6(3):285-304. PubMed ID: 19327045
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Polyclonal anti-idiotypic antibodies which mimic an epitope of the human prion protein.
    Hanoux V; Wijkhuisen A; Alexandrenne C; Créminon C; Boquet D; Couraud JY
    Mol Immunol; 2009 Mar; 46(6):1076-83. PubMed ID: 19012967
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Methods for comprehensive identification of membrane proteins recognized by a large number of monoclonal antibodies.
    Kurosawa G; Sumitomo M; Akahori Y; Matsuda K; Muramatsu C; Takasaki A; Iba Y; Eguchi K; Tanaka M; Suzuki K; Morita M; Sato N; Sugiura M; Sugioka A; Hayashi N; Kurosawa Y
    J Immunol Methods; 2009 Dec; 351(1-2):1-12. PubMed ID: 19766650
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Stem cell markers: insights from membrane proteomics?
    Ahn SM; Goode RJ; Simpson RJ
    Proteomics; 2008 Dec; 8(23-24):4946-57. PubMed ID: 19016515
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Preclinical characterization of SGN-70, a humanized antibody directed against CD70.
    McEarchern JA; Smith LM; McDonagh CF; Klussman K; Gordon KA; Morris-Tilden CA; Duniho S; Ryan M; Boursalian TE; Carter PJ; Grewal IS; Law CL
    Clin Cancer Res; 2008 Dec; 14(23):7763-72. PubMed ID: 19047103
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Reverse transfection using antibodies against a cell surface antigen in mammalian adherent cell lines.
    Uchimura E; Yamada S; Nomura T; Matsumoto K; Fujita S; Miyake M; Miyake J
    J Biosci Bioeng; 2007 Aug; 104(2):152-5. PubMed ID: 17884662
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Proteomics: new technologies and clinical applications.
    Latterich M; Abramovitz M; Leyland-Jones B
    Eur J Cancer; 2008 Dec; 44(18):2737-41. PubMed ID: 18977654
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Protein-binding microarrays: probing disease markers at the interface of proteomics and genomics.
    Kerschgens J; Egener-Kuhn T; Mermod N
    Trends Mol Med; 2009 Aug; 15(8):352-8. PubMed ID: 19665433
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Structure-based design of molecular cancer therapeutics.
    van Montfort RL; Workman P
    Trends Biotechnol; 2009 May; 27(5):315-28. PubMed ID: 19339067
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Anti-tumoral effect of active immunotherapy in C57BL/6 mice using a recombinant human VEGF protein as antigen and three chemically unrelated adjuvants.
    Morera Y; Bequet-Romero M; Ayala M; Lamdán H; Agger EM; Andersen P; Gavilondo JV
    Angiogenesis; 2008; 11(4):381-93. PubMed ID: 19034678
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Brain tumor stem cells as research and treatment targets.
    Hide T; Takezaki T; Nakamura H; Kuratsu J; Kondo T
    Brain Tumor Pathol; 2008; 25(2):67-72. PubMed ID: 18987831
    [TBL] [Abstract][Full Text] [Related]  

  • 32. New frontiers in cell-based immunotherapy of cancer.
    D'Elios MM; Del Prete G; Amedei A
    Expert Opin Ther Pat; 2009 May; 19(5):623-41. PubMed ID: 19441938
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Influence of size, surface, cell line, and kinetic properties on the specific binding of A33 antigen-targeted multilayered particles and capsules to colorectal cancer cells.
    Cortez C; Tomaskovic-Crook E; Johnston AP; Scott AM; Nice EC; Heath JK; Caruso F
    ACS Nano; 2007 Sep; 1(2):93-102. PubMed ID: 19206525
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Identification of a novel tumor-associated antigen, cadherin 3/P-cadherin, as a possible target for immunotherapy of pancreatic, gastric, and colorectal cancers.
    Imai K; Hirata S; Irie A; Senju S; Ikuta Y; Yokomine K; Harao M; Inoue M; Tsunoda T; Nakatsuru S; Nakagawa H; Nakamura Y; Baba H; Nishimura Y
    Clin Cancer Res; 2008 Oct; 14(20):6487-95. PubMed ID: 18927288
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Screen of multifunctional monoclonal antibodies against hepatitis B core virus-like particles.
    Sun C; Ding FX; Wang F; He XW; He Y; Li ZS; Sun SH
    Microbiol Immunol; 2009 Jun; 53(6):340-8. PubMed ID: 19493202
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The use of gene array technology and proteomics in the search of new targets of diseases for therapeutics.
    Ferrer-Alcón M; Arteta D; Guerrero MJ; Fernandez-Orth D; Simón L; Martinez A
    Toxicol Lett; 2009 Apr; 186(1):45-51. PubMed ID: 19022361
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Antibody therapy for hematopoietic malignancies and cell surface antigen testing].
    Higashi K
    Rinsho Byori; 2014 Apr; 62(4):352-8. PubMed ID: 25022064
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Post genomics - from antibody production to small molecule discovery.
    Romano A; McAlpine J; Ecker D
    Curr Opin Drug Discov Devel; 2008 Mar; 11(2):166-7. PubMed ID: 18283603
    [No Abstract]   [Full Text] [Related]  

  • 39. Antibody engineering principles and applications.
    Loo L; Robinson MK; Adams GP
    Cancer J; 2008; 14(3):149-53. PubMed ID: 18536554
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Submitting antibodies to binding arbitration.
    Michnick SW; Sidhu SS
    Nat Chem Biol; 2008 Jun; 4(6):326-9. PubMed ID: 18488004
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.